Pharmaceutical Business review

Anzag acquires 92% stake in Armila

Following recent acquisitions in Croatia and Romania, the purchase of Armila is said to represent the latest stage in Anzag’s strategy to establish itself in carefully targeted high-growth markets.

Thomas Trumper, chairman of the board at Anzag, said: “By acquiring Armila, we are expanding our business in foreign markets, and so reducing our dependency on our home market of Germany, and our vulnerability to cyclical fluctuations here.”